IceCure Medical Launches Pioneering Study for Low-Risk Breast Cancer Treatment in the U.S.

IceCure Medical Initiates the 'ChoICE' Study

IceCure Medical Ltd., a company recognized for its advanced cryoablation technologies, has commenced its post-marketing study dubbed 'ChoICE' at the West Cancer Center Research Institute in Germantown, Tennessee. This initiative marks a significant step in enhancing treatment options for low-risk breast cancer after the U.S. Food and Drug Administration granted marketing authorization for their treatment, ProSense®, in October 2025.

What is the ChoICE Study?

The ChoICE Study aims to gather real-world data from up to 400 participants across 30 locations in the U.S. This study will focus on patients aged 70 and above with low-risk, early-stage breast cancer. The objective is to further support the adoption of ProSense® cryoablation therapy, a minimally invasive procedure that destroys tumors by freezing them instead of traditional surgical methods.

Dr. Richard Gilmore, MD, MBA, DipABLM, a prominent breast surgical oncologist at the Margaret West Comprehensive Breast Center, will lead the site in Germantown. IceCure's CEO, Eyal Shamir, expressed confidence in the collaboration with West Cancer Center, highlighting that each new study site reinforces their commitment to expanding access to innovative cancer treatments for eligible patients.

The Role of ProSense® Cryoablation

ProSense® has been specifically designed to treat low-risk tumors measuring 1.5 cm or less in size in patients aged over 70. This treatment not only offers a viable alternative to surgical options but also appeals to a demographic seeking less invasive methods while still ensuring effective care. The ChoICE Study not only validates the use of ProSense® in clinical settings but also aims to produce additional data to boost its utility in general practice.

By using a dual approach, the designated study sites will operate as active commercial centers as well. This means participants can receive treatment regardless of their involvement in the study, significantly broadening the scope of access to this groundbreaking technology.

IceCure's Future and Commitment

The initiation of the ChoICE Study reflects IceCure Medical’s dedication to leading the advancement of evidence-based care for breast cancer—one of the most prevalent forms of cancer among women worldwide. With a robust clinical trial program in place, IceCure continually seeks insights from real-world applications of their technologies to ensure they meet the high standards of care that patients deserve.

IceCure Medical's efforts underscore the necessity for continued innovation in cancer treatment, especially for older patients who may be more vulnerable to the complications associated with surgery. The company’s vision illustrates how modern medical technology can reshape treatment landscapes for various types of cancer, placing a significant emphasis on patient-centered care.

IceCure Medical specializes in developing cryoablation treatment systems that cater to a variety of cancers, including breast, kidney, lung, and bone cancer. Their focus on minimally invasive options positions them at the forefront of a movement favoring patient-friendly treatments.

With the ChoICE Study underway, IceCure Medical stands committed to transforming how low-risk breast cancer is treated across the nation, fostering a brighter and healthier future for patients in need. As results from this study unfold, they may pave the path toward more widespread acceptance and application of cryoablation as a first-line option in the treatment of low-risk breast cancer.